With approximately 101 million individuals living with diabetes, increasing access to insulin and advanced treatments is ...

The trial results are among the pharmaceutical industry's most critical and closely watched of the year, as they bring Eli Lilly's drug one step closer to becoming a new, needle-free alternative ...

Crunching the data, the news looks relatively worse for Novo Nordisk and relatively better for rivals Eli Lilly and Him & Hers Health. First, Novo Nordisk is expanding its program to sell Wegovy ...

Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could be pivotal for the obesity treatment market due to its accessibility.

Zepbound is Eli Lilly's biggest growth driver at the moment, but it isn't the only drug pushing total sales higher for this well-established pharmaceutical giant. Its fourth-quarter revenue not ...

LOS ANGELES, CA – Lilly Singh is back with another game-changer. The YouTube star-turned-entrepreneur has launched HYPHEN8, a media network built to help South Asian content creators thrive.

Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be presented at the American Association for Cancer ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best stocks to buy now for the long term. The US equity markets have started to show ...

to Eli Lilly and Company (NYSE:LLY) ("Lilly”). The transaction was completed on March 25, 2025. With the closing, Organovo receives an upfront payment, with future milestones to be paid as FXR314 hits ...